Research programme: therapeutic agents - Whanin Pharmaceuticals

Drug Profile

Research programme: therapeutic agents - Whanin Pharmaceuticals

Alternative Names: WIB-1001C; WIB-801C; WIB-901H; WIN-1001X; WIN-902A; WIP-901; WIP-901C

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Whanin Pharmaceutical
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity; Stroke
  • Research Dementia; Hepatitis C
  • Discontinued Hyperlipidaemia; Neurodegenerative disorders; Osteoarthritis

Most Recent Events

  • 06 Oct 2016 WIB 1001C is still in research development for Dementia in South Korea (Whanin Pharmaceuticals pipeline, October 2016)
  • 06 Oct 2016 WIB 801C is still in preclinical development for Stroke in South Korea (Whanin Pharmaceuticals pipeline, October 2016)
  • 06 Oct 2016 WIN 902A is still in preclinical development for Obesity in South Korea (Whanin Pharmaceuticals pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top